Thursday, September 18, 2025 

12:00 pm – 1:00 pm CT / 1:00 pm – 2:00 pm ET

Register 

Cost: FREE for SIDP Members! $10 for non-member attendees

Invasive fungal infections are associated with significant morbidity, mortality, and healthcare costs, particularly among immunocompromised and critically ill patients. Despite the availability of potent antifungal agents, inappropriate use—including empiric overuse, incorrect dosing, and prolonged therapy—contributes to antifungal resistance, toxicity, and suboptimal clinical outcomes. Effective antifungal stewardship is essential to optimize the selection, dosing, and duration of therapy while minimizing adverse effects and resistance. Therapeutic drug monitoring (TDM) is a key component of antifungal stewardship for agents such as voriconazole, posaconazole, and flucytosine, where there is a well established relationship between drug exposure, efficacy, and toxicity. However, implementation of TDM remains inconsistent across institutions, and many pharmacists report uncertainty regarding when to initiate monitoring, how to interpret serum concentrations, and how to adjust dosing based on pharmacokinetic and clinical factors.

The goal of this session is to equip pharmacists with knowledge and skills to optimize antifungal therapy through effective stewardship strategies and application of therapeutic drug monitoring for agents commonly used in the treatment of invasive fungal infections.

Target Audience:

This activity was planned to meet the educational needs of pharmacists practicing in adult and pediatric settings; ID-specialized pharmacists; critical care-, transplant-, and oncology-specialized pharmacists.

• Apply antifungal stewardship principles to institutional protocols to optimize agent selection, dosing, and duration of therapy in patients with invasive fungal infections.
• Interpret antifungal serum concentration data to guide therapeutic drug monitoring for antifungal agents.
• Identify and manage clinical scenarios where therapeutic drug monitoring is critical for maximizing efficacy and minimizing toxicity of antifungal agents in immunocompromised or critically ill patients.

Faculty:

Daniel B. Chastain, PharmD, BCIDP
Clinical Associate Professor  
Clinical and Administrative Pharmacy 
University of Georgia College of Pharmacy  - Augusta Campus
Augusta, GA 

Melissa D. Johnson, PharmD, MHS
Professor in Medicine and Liaison Clinical Pharmacist
Division of Infectious Diseases and International Health
Duke University Medical Center and Duke Antimicrobial Stewardship Outreach Network
Durham, NC

Accreditation:

Pharmacist

The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0672-0000-25-015-L01-P
CPE credit: 1.0 contact hour (0.1 CEU)
Type of activity: Application
ACPE Activity Fee: SIDP Member: Free / Non-Member: $10

To receive CE credit, participants must view the CE content, complete a post-test with a passing score of 70% or greater, and complete an evaluation. Proof of completion will be submitted to NABP CPE Monitor.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.

Funding:

This activity is provided by SIDP. No external funding was received for this activity.

Disclosures:

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:

• Dr.  Chastain's and Dr Johnson's disclosures will be announced prior to the start of the activity.
• SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.
• Presentation title and objectives were written by the planning committee and enhanced by AI. All enhancements were reviewed by a human.

Disclaimer:

Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.

The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.